BrainCheck vs Linus Health (2026)
Both sell digital cognitive assessment under the same FDA classification, a Class II exempt listing for computerized cognitive assessment aids, and both position the result as an aid rather than a diagnosis. BrainCheck Assess is a standardized battery of digital tasks covering memory, executive function, attention, mental flexibility and processing speed, with care planning built around the result. Linus Health scores drawing, speech and stylus behavior with machine learning. Its Core Cognitive Evaluation pairs a three minute Digital Clock and Recall test with a life and health questionnaire, and returns a provider report with the recordings behind the score, an action plan and care pathway guidance. Choose BrainCheck for a broader battery tied to care planning; choose Linus Health for a short test whose scoring reads how the patient draws and speaks.
- You want a broader battery across memory, attention, flexibility and processing speed.
- Results should feed a care plan for the patient.
- Assessment and follow up should sit in one platform.
- A test of about three minutes suits a busy primary care visit.
- Scoring should read drawing, speech and stylus behavior, with the recordings kept.
- The report should include an action plan and care pathway guidance.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BrainCheck and Linus Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BrainCheck | Linus Health |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | 2015 | 2019 |
| Headquarters | Austin, Texas, United States | Boston, Massachusetts, United States |
| Website | braincheck.com | linushealth.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Digital cognitive assessment and care planning platform. The flagship product, BrainCheck Assess, is a Class II, 510(k)-exempt computerized cognitive assessment aid regulated by the FDA, indicated as an aid in the assessment of cognitive impairment and explicitly not intended as a standalone diagnostic tool.
Source: AI Health Index, September 2026
Digital cognitive assessment platform that scores drawing, speech and stylus behavior with machine learning models. The flagship Core Cognitive Evaluation combines the Digital Clock and Recall (DCR), a clock drawing and three word recall test of about three minutes built on the DCTclock, with a Life and Health Questionnaire, and returns a provider report with the recordings behind the score, a personalized action plan and care pathway guidance.
Source: AI Health Index, September 2026
Questions buyers ask
How do BrainCheck and Linus Health work with the EHR?
For BrainCheck, the named list stops at those two, and the company notes some feature availability is determined by EHR integration, meaning capability varies by platform.
With Linus Health, the athenahealth Marketplace release (June 2023) says the platform is integrated with athenaOne so results appear in the EHR, with Healthtopia Clinics quoted on results arriving in its record, and a neurology chair at an unnamed California health system describes integration with Cerner on the health systems page. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do BrainCheck and Linus Health handle patient data?
Assessment data is handled under role based access controls with activity logging, encrypted in transit and at rest, and BrainCheck states that retention and deletion can be aligned to customer contractual requirements.
Against that, the terms and conditions of sale grant the company a perpetual, irrevocable license to use customer data in aggregated, de-identified form "for the sole purpose of enhancing and improving the Linus Health Services", and the terms of use allow personal data to be used to test, benchmark, enhance and improve products. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for BrainCheck and Linus Health?
With BrainCheck, a later analysis found a Pearson correlation of 0.77 against the Montreal Cognitive Assessment with a confidence interval reported. A 529 participant study across four United States clinical sites, run with BrainBox Solutions and registered as NCT04423198, tested test retest reliability and concurrent validity against the corresponding paper instruments.
In Linus Health's case, the 2024 Bio-Hermes paper (706 participants) reports AUC 0.70 for the DCR against 0.63 for the MMSE. Both papers are led by company staff with the co-founders among the authors, and the underlying study data are governed by the Global Alzheimer's Platform. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How much do BrainCheck and Linus Health leave to the clinician?
For BrainCheck, the company states that the assessment is not intended for use as a standalone diagnostic tool, that it is designed to support clinical interpretation rather than replace it, and that structured cognitive data is meant to be read alongside history, examination findings and functional status rather than in isolation.
With Linus Health, the terms of use state the platform is not intended as a stand-alone or adjunctive diagnostic device and is not intended to determine the level or type of care, and the company's 2024 paper sets the DCR impairment threshold at a score of 3 or below. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Neither publishes a price. Both are listed with FDA as Class II exempt devices under the same classification, not cleared through 510(k).
Ask both how their results compare with a full neuropsychological evaluation, and in which populations.